SecBot SecBot
SECBOTREPLAY Home › Report › GSK

GSK · GSK filed a routine Form 6-K on June 11, 2026, disclosing eight PDMR…

GSK plc · 6-K filed Jun 11, 2026 at 10:42 ET

At the news

NEUTRALIMPACT 1/10

6-K filed Jun 11, 2026 at 10:42 ET

GSK filed a routine Form 6-K on June 11, 2026, disclosing eight PDMR transactions under the company's Share Reward Plan. Seven senior executives and one PCA acquired a total of 110 ordinary shares at £18.8393 per share on June 9, 2026. These are formulaic, pre-planned plan acquisitions, not discretionary open-market buys, with trivial aggregate value (~£2,070). The filing carries no material financial or strategic content.

  • Filed June 11, 2026, reporting transactions from June 9, 2026.
  • Eight PDMRs/PCA acquired shares: Lynn Baxter, Julie Brown (CFO), James Ford, David Redfern, Regis Simard, Philip Thomson, Deborah Waterhouse, Victoria Whyte, and Neil Falkingham (PCA of Lynn Baxter).
  • Type: acquisition under GSK's Share Reward Plan (partnership + matching shares).
  • Share price: £18.8393 per share; individual acquisitions range from 12 to 14 shares.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access